Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Phase III Study of Ipilimumab 3 mg/kg vs 10 mg/kg in Unresectable or Metastatic Melanoma
2011-004029-28Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ipilimumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival. Started Dec 2011; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2011-004029-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004029-28.